1421314-72-8

Upstream product

• 1421314-66-0 5-benzyloxy-N-(4-fluorobenzyl)-6-hydroxymethyl-4-oxo-1,4-dihydropyridine-3-carboxamide 
• 906658-35-3 methyl 5-benzyloxy-6-hydroxymethyl-4-oxo-1,4-dihydropyridine-3-carboxylate 
• 906657-90-7 methyl 4-acetoxy-6-acetoxymethyl-5-benzyloxynicotinate 
• 906657-89-4 methyl 4-acetoxy-5-benzyloxy-6-methyl-1-oxynicotinate 
• 100-39-0 benzyl bromide 
• 118-71-8 Maltol 
• 906657-88-3 methyl 4-acetoxy-5-benzyloxy-6-methylnicotinate 
• 1421314-65-9 methyl 5-benzyloxy-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylate 
• 1421314-64-8 3-(benzyloxy)-5-bromo-2-methylpyridin-4(1H)-one 
• 61160-18-7 3-benzyloxy-2-methyl-1H-pyridin-4-one 
• 61049-69-2 3-O-benzylmaltol 
• 906657-97-4 methyl 1-allyl-3-benzyloxy-5-(4-fluorobenzylcarbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 906657-95-2 3-benzyloxy-5-(4-fluorobenzylcarbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid 
• 1421314-67-1 5-benzyloxy-N-(4-fluorobenzyl)-6-formyl-4-oxo-1,4-dihydropyridine-3-carboxamide 

Downstream Products

• 1309559-57-6 C₂₁H₂₃FN₄O₄ 

Relevant academic research and scientific papers

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles

This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties. We report herein a series of